Currently, the company is recruiting around 125 patients in a multi-national ongoing Phase 2 study of NKTR-102 in patients with platinum-resistant ovarian cancer whose disease has progressed after treatment with pegylated liposomal doxorubicin (PLD) therapy.
Nektar plans to initiate a Phase 3 trial of NKTR-102 in patients with ovarian cancer soon.
Nektar Drug Development and Regulatory Affairs vice president Carlo DiFonzo said they are pleased to have received a positive opinion from COMP for orphan medicinal product status in Europe to augment the US Orphan Drug Designation recently received in April, as they continue the treatment of patients in their Phase 2 study of NKTR-102 in women with platinum-resistant ovarian cancer.